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Abstract
Background: Sexually transmissible infection (STI) and blood-borne virus (BBV) diagnoses data are a core
component of the Australian National Notifiable Diseases Surveillance System (NNDSS). However, the NNDSS data
alone is not enough to understand STI and BBV burden among priority population groups, like Aboriginal and
Torres Strait Islander people, because it lacks testing, treatment and management data. Here, we describe the
processes involved in establishing a STI and BBV sentinel surveillance network representative of Aboriginal
Community-Controlled Health Services (ACCHS)—known as the ATLAS network—to augment the NNDSS and to
help us understand the burden of disease due to STI and BBV among Aboriginal and Torres Strait Islander peoples.
Methods: Researchers invited participation from ACCHS in urban, regional and remote areas clustered in five
clinical hubs across four Australian jurisdictions. Participation agreements were developed for each clinical hub and
individual ACCHS. Deidentified electronic medical record (EMR) data relating to STI and BBV testing, treatment and
management are collected passively from each ACCHS via the GRHANITEtm data extraction tool. These data are
analysed centrally to inform 12 performance measures which are included in regular surveillance reports generated
for each ACCHS and clinical hub.
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Results: The ATLAS network currently includes 29 ACCHS. Regular reports are provided to ACCHS to assess clinical
practice and drive continuous quality improvement initiatives internally. Data is also aggregated at the hub,
jurisdictional and national level and will be used to inform clinical guidelines and to guide future research
questions. The ATLAS infrastructure can be expanded to include other health services and potentially linked to
other data sources using GRHANITE.
Conclusions: The ATLAS network is an established national surveillance network specific to Aboriginal and Torres
Strait Islander peoples. The data collected through the ATLAS network augments the NNDSS and will contribute to
improved STI and BBV clinical care, guidelines and policy program-planning.
Keywords: Aboriginal and Torres Strait Islander, First Peoples, Primary Care, Sexually Transmissible Infection, Blood-
borne Virus, Surveillance, Reporting
Background
Aboriginal and Torres Strait Islander (hereafter, respectfully,
Aboriginal) people represent 3% of Australia’s total popula-
tion [1] and are recognised as the First Peoples of Australia.
The overall health status of Aboriginal peoples is poor in
comparison to the non-Aboriginal population, an inequality
largely driven by the ongoing impact of colonisation and
poor progress in achieving equitable outcomes in social, cul-
tural and economic determinants of health [2].
Aboriginal people are identified as a priority population for
control of sexually transmissible infections (STI) and blood-
borne viruses (BBV) because the burden of these diseases
among Aboriginal peoples is much higher than in other pop-
ulations in Australia [3]. Diagnosis rates of chlamydia and
gonorrhoea are reported at between 3–5 and 3–30 times
higher than those for non-Aboriginal Australians, respect-
ively. An ongoing syphilis outbreak spanning four jurisdic-
tions and amassing over 2400 cases since 2011 continues to
predominantly affect Aboriginal heterosexual people aged
16–29 years living in remote communities of Australia [4].
Further, increasing notification rates of both hepatitis C and
HIV among Aboriginal people are of concern, given that
over the last five years, diagnoses rates among non-
Aboriginal people have stabilised or decreased [3]. Accord-
ingly, proactive approaches to diagnose and treat STI and
BBV in Aboriginal populations are required.
As in many other settings, our current understanding of
STI and BBV epidemics in Australia is deduced from diag-
noses data alone. Once a diagnosis is made for a notifiable
infection (e.g. chlamydia, gonorrhoea, trichomonas, HIV,
viral hepatitis), it is a legislative requirement of medical
officers or laboratories to report to jurisdictional health
departments. These data are then aggregated and reported
by key demographic characteristics, including Aboriginal
status, periodically at the jurisdictional level and nation-
ally. While it is acknowledged that these systems are an
important component of infectious diseases surveillance
in Australia, there are several constraints of the system.
Most notably, the absence of STI and BBV testing data
prevents the ability to contextualise changes in diagnoses
data or, in the case of hepatitis C, rates of cure. Further,
the system is not complete for Aboriginal status in some
of the more populous jurisdictions, and thus may be in-
accurately reporting the burden of disease [3, 5].
Together, these limitations impact the use of the NNDSS
in assessing the burden of disease among populations, the
impact of public health and clinical interventions, or for
assessing clinical care and management.
Primary health care services in Australia diagnose most
STI and BBV nationally and are supported by a compre-
hensive set of clinical guidelines at both a jurisdictional
and national level [6–8]. Accordingly, primary care
services routinely collect testing, diagnosis, treatment and
management data related to STI and BBV. These data are
an incredibly valuable but underutilised resource and can
be used to help drive clinical and public health interven-
tions [9], as well as provide greater understanding of
epidemics, especially among priority populations.
A strength of the Australian healthcare system is the
extensive network of Aboriginal Community-Controlled
Health Services (ACCHS), established to deliver cultur-
ally appropriate health care for Aboriginal people [10].
There are over 140 ACCHS across Australia, providing a
diverse range of primary care services, spanning medical
care, allied health, health promotion and outreach services,
to Aboriginal communities. It is estimated that ACCHS
provide more than 2.5 million episodes of care annually to
around 50% of the total national Aboriginal population
[11]. Accordingly, participation of ACCHS is a critical com-
ponent of any research activity seeking to address disease
burden in Aboriginal communities.
In this paper we describe the establishment of a senti-
nel STI and BBV surveillance network of ACCHS and
other relevant primary care services in Australia—known
as the ATLAS network.
Methods
ATLAS network objective and rationale
The objective of the ATLAS network is to collate data to
supplement the NNDSS and contribute to improved
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understanding of local, regional and national patterns of
clinical care of STI and BBV among Aboriginal people.
Participating research partners
We invited five peak Aboriginal health organisations repre-
senting regional areas in four Australian jurisdictions to part-
ner in this research. The four jurisdictions include
Queensland, South Australia, New South Wales and West-
ern Australia. Each organisation represents the views of mul-
tiple ACCHS within their geographical remit and agreed to
act as ‘clinical hubs’ for this research. The five clinical hubs
are Apunipima Cape York Health Council in northern
Queensland; the Institute of Urban Indigenous Health
(IUIH) in south-eastern Queensland; the Aboriginal Health
and Medical Research Council of New South Wales; the
Aboriginal Health Council of South Australia and the Kim-
berley Aboriginal Medical Services (KAMS) in Western
Australia (Fig. 1). These hubs were chosen based on conveni-
ence, geographic location and existing collaborative relation-
ships with the research team. Each clinical hub is committed
to oversight of the ATLAS network and other research gen-
erated as part of the study. It is our intention that the net-
work expand over time.
Site engagement
The research team has committed to an extensive and
ongoing community and site engagement process, which
commenced while the funding proposal was being devel-
oped. Executive staff, sexual health/population health
specialist staff and other management from the five clin-
ical hubs and individual ACCHS were consulted about
their organisation’s participation in the ATLAS network.
Each ACCHS’s governing Board approved participation
in the network.
Research governance and ethics
Formal approvals have been obtained from six Human
Research Ethics Committee (HRECs) and regional research
governance groups to date, including three Aboriginal-
specific HRECs: the Aboriginal Health Research Ethics Com-
mittee in South Australia (EC00185, approval 04–17-732);
the Aboriginal Health and Medical Research Ethics Commit-
tee (EC00342, approval 1300/17); and the Western Austra-
lian Aboriginal Health Ethics Committee (EC00292, approval
805, following approval from the Kimberley Aboriginal
Health Planning Forum’s Research Subcommittee). Permis-
sions were also obtained from the Far North Queensland
Human Research Ethics Committee (as Queensland Health
provides much of the primary care services in Aboriginal
communities where the Apunipima Cape York Health
Council is also active—EC00157, approval HREC/17/QCH/
102–1173) and the Flinders University Social and Behav-
ioural Research Ethics Committee (as the Lead Investigator’s
affiliated institution—EC00194, approval OH-00142).
Fig. 1 Map of CRE-ASH /ATLAS clinical hubs (image adapted from Google Earth v7.3 [12]. Map data: NASA, TerraMetrics©2020. Used in
accordance with http://www.google.com/permissions/geoguidelines/)
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A Clinical Hub Reference Group, consisting of repre-
sentatives from each clinical hub, provides critical over-
sight of and input to all research activities.
Operation of the ATLAS network
The ATLAS network routinely collects clinical data from
participating ACCHS via their electronic medical record
(EMR). ACCHS in the network contribute deidentified
patient records relating to clinical care (testing, treatment
and management) for in-scope STI and BBV either
directly from the ACCHS’s EMR or via the third-party
data extraction tool GRHANITEtm. EMR generally do not
have the capacity to extract and analyse population-level
STI and BBV data internally, sufficient to evaluate clinical
practice and inform Continuous Quality Improvement
(CQI). The ATLAS network provides this capacity.
Most EMR require the use of third-party software to
perform the extraction and delivery of relevant data in a
standardised manner. We explored several different
commercially-available data extraction tools—including
software developed by the Improvement Foundation [13]
and Pen CS [14]—before opting for the University of
Melbourne’s GRHANITE software [15]. GRHANITE offered
significant advantages over other software products includ-
ing; compatibility with most of the EMR used in the ACCHS
sector, capacity to deliver line-listed data, a substantial history
of use by other sexual health research and surveillance pro-
jects [16–18], and best-practice approaches to patient dei-
dentification and data encryption [9, 19].
For our network, the hash-based deidentification
process was a key feature as it is thought to be more
secure than the Australian Government’s SLK581 [20],
retaining no element of personal information in the
hashed identifier, yet still facilitates person-based linkage
across the ATLAS network irrespective of the clinic from
which the data originate. Similarly, the GRHANITE
hashed identifier also can facilitate linkage to other
projects and/or health services using GRHANITE. More-
over, the highly automated data collection process reduces
workload for the research team once the surveillance in-
frastructure is established and enables further automation
of the analysis and reporting system.
The initial data extraction from an ATLAS site collects
data from 1 January 2016 to the date of extraction,
followed by ongoing, regular (ideally, weekly) extractions.
Deidentified EMR data are transferred to the ATLAS
project’s secure databank located at the South Australian
Health and Medical Research Institute (SAHMRI) and
cleaned and stored for analysis. The ATLAS data
processes utilise a custom-built SQL server accessing R
Studio and Stata scripts interfacing with MS Word to pro-
duce standardised analyses for all sites participating in the
surveillance network.
Data analysis
The STI currently included in the ATLAS project are
chlamydia, gonorrhoea, trichomonas, syphilis and HIV.
The BBV currently included in ATLAS are hepatitis B
and hepatitis C (in addition to HIV).
An initial suite of 12 STI and BBV performance
measures have been developed for the ATLAS network’s
surveillance reports using a co-design process with the
clinical hub network (see Table 1). These performance
measures are reflective of national clinical guidelines [6,
7], have a strong basis in previous research in the sector
[21–28] and align with the Fifth National Aboriginal and
Torres Strait Islander Blood Borne Viruses and Sexually
Transmissible Infections Strategy 2018–2022’s goals re-
garding surveillance of existing and emerging STI and
BBV issues and challenges among Aboriginal communi-
ties [29]. Refinement of these performance measures is
an iterative and ongoing process conducted in collabor-
ation with clinical hubs and services contributing to the
ATLAS project but is necessarily limited to surveillance
of standard clinical items that can be extracted from pa-
tient management systems.
Baseline reports addressing the current 12 perform-
ance measures, including their sub-analyses and disag-
gregations, were calculated and drafts provided to
clinical hub/health service staff for feedback before
finalisation. Suggestions for improvements were im-
mediately incorporated into our analysis and reporting
templates where feasible and we continue to refine our
processes based on ongoing feedback to maximise




To date, 29 ACCHS have joined the ATLAS surveillance
network, representing 34 individual clinics and all five
clinical hubs. Accordingly, participating ACCHS repre-
sent a wide geographical spread, covering metropolitan,
regional, remote and very remote communities. ATLAS
currently includes a slightly lower proportion of ACCHS
from regional communities than would be expected
from the population of all Aboriginal-specific primary
care services [11]. Patient populations for these ACCHS
range from 420 to 11,200 clients (Table 2).
Some concerns, primarily relating to the integrity of
clinical data being extracted from patient records, and
safety and storage of data extracted from EMR offsite for
analysis, were raised by individual ACCHS and clinical
hub representatives during site engagement consultations.
Conversely, ACCHS and clinical hubs welcomed positive
aspects of the network, including: the ability to have
patient data collated at the ACCHS level; the opportunity
to participate in the development of the 12 performance
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measures; the ability to benchmark their service with simi-
lar primary health care services; and having data available
for STI and BBV to integrate within other CQI activities
already underway within their health service.
Data extraction from ACCHS
Four different EMR have been encountered in the ATLAS
network to date: CommuniCaretm, Best Practicetm, Medical
Directortm and MMExtm. The first three of these EMR do
not have the capacity to readily extract deidentified line-
listed patient data for specific research projects and re-
quired development of specific GRHANITE interfaces to
facilitate this. The MMEx EMR, the principal system used
by ATLAS’s IUIH (Brisbane) and KAMS (Kimberley)
clinical hubs, is able to extract and export deidentified line-
listed data in the form of .csv files via the proprietary ISA
Insights reporting tool. Nevertheless, the increased privacy
and linkage capabilities of the GRHANITE tool are consid-
ered to have advantages over MMEx’s internal systems and
the ATLAS team has worked with GRHANITE’s devel-
opers, and key data management staff in the relevant
clinical hubs, to also design and implement an interface for
the MMEx EMR to take advantage of this highly desirable
functionality.
Data analysis and reporting
Irrespective of the mode of data delivery (GRHANITE
or direct-export), baseline surveillance reports address-
ing the current 12 performance measures are developed
for each ACCHS on entry to the surveillance network
and ongoing surveillance reports provided at regular
intervals thereafter. ACCHS that joined ATLAS early
were provided with baseline reports covering 1 January
2016 to 31 December 2017 while later entrants had this
baseline period brought forward to 1 January 2017 to 31
December 2018. Early baseline reports have also been
updated to match this timeframe. New data are extracted
at regular and ongoing intervals, and six-monthly reports
are prepared for participating ACCHS approximately
three months after the focal time-period occurs, to allow
for record finalisation and assessment of appropriate
follow-up. Newly-imported data are automatically proc-
essed to clean the data and apply transformations to align
to a standard data structure. The synthesised database can
Table 2 Current site engagement descriptors for ATLAS STI and
BBV surveillance network
Clinical Hub ACCHS N Patient
Populations
Range
Apunipima Cape York Health Council 11 450–4470
Institute of Urban Indigenous Health 2 4820–7640
Aboriginal Health and Medical Research
Council of New South Wales
3 3700–4830
Aboriginal Health Council of South Australia 6 320–7800
Kimberley Aboriginal Medical Services 7 420–11,220
Table 1 ATLAS surveillance reporting Performance Measures
Performance measures Definition
1. STI Testing Rate Proportion of clients tested for STIs (CT, NG, TV, syphilis and HIV) during the reporting period
2. STI Testing Coverage Proportion of current clients tested for STIs at least once in a 12-month period
3. STI test positivity Proportion of clients with at least one positive STI test in a 12-month period
4. Completeness of STI Testing Proportion of clients with a positive CT and/or NG and/or TV result also tested for syphilis and
HIV within 30 days of date of initial specimen collection
5. STI Treatment Interval Time (days) from date of positive STI (CT, NG, TV) test to date of treatment
6. STI Retesting Rate Proportion of clients retested at approximately three months (60 to 120 days) following
treatment for an initial positive STI (CT/NG/TV) result
7. STI Repeat Positivity Rate Proportion of clients retested at approximately three months (60 to 120 days) after treatment
for an initial positive CT/NG result and who retested positive for CT/NG at this time
8. Hepatitis B Virus (HBV) Testing Rate Proportion of clients receiving an HBV test. Among those testing negative, the proportion who
subsequently received one or more dose of vaccination.
9. Hepatitis C (HCV) Testing Rate Proportion of clients receiving an HCV antibody test and among those testing positive, the
proportion then tested for RNA or viral load.
10. HCV Treatment Uptake Proportion of HCV RNA positive clients prescribed Direct Acting Antiviral (DAA) treatment
11. HCV Sustained Virological Response Proportion of clients who, after having been prescribed DAA treatment, achieve an
undetectable viral load
12. HPV Screening Rate Proportion of female clients screened for human papillomavirus in line with national
guidelines
Clients: all patients aged 15 years or older attending the health service for a clinical encounter or consultation with a medical doctor, nurse or Aboriginal
health practitioner
Abbreviations: CT Chlamydia trachomatis, DAA Direct Acting Antiviral, HBV Hepatitis B Virus, HCV Hepatitis C Virus, HIV Human Immunodeficiency Virus, HPV
Human Papillomavirus, NG Neisseria gonorrhoeae, STI Sexually Transmissible Infection, TV Trichomonas vaginalis
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then be used to produce health service-specific analyses or
analyses at a more aggregated level, such as benchmarking
within individual clinical hubs as well as comparisons
across the ATLAS network more widely (e.g. analyses by
remoteness or grouped by patient population size).
The research team are currently developing an analysis
and reporting infrastructure whereby ACCHS can access
a secure online dashboard and generate their own ana-
lyses and reports. This will not only give ACCHS greater
control over their own data and the analyses of most
relevance to their practice, it will also capitalise on the
ATLAS network’s capacity to update GRHANITE ex-
tractions on a weekly basis, thus improving the timelines
for return of the data.
Discussion
The ATLAS network is one of the largest clinical
surveillance networks operating in Australian ACCHS.
Establishment of the ATLAS network has been a justifi-
ably lengthy process with regular communication, con-
sultation and feedback required of ACCHS and clinical
hubs. Engagement with relevant research governance
and ethical review committees across the network was
also a lengthy and complex process. Five separate ap-
proval pathways needed to be followed, with the inher-
ent complication of changes required by one research/
ethics committee needing to be replicated across the
network to ensure uniformity, which was often difficult
to achieve when approval of the protocol was already in
train or had been granted (and implemented) in other
parts of the network. The achievements of the ATLAS
project in the first half of its funding period must be
viewed with consideration of the lengthy time required
for these negotiations.
The ATLAS network returns data to health services
on a regular basis, for use in evidence-based CQI
processes applying a ‘plan-do-check-act’ cycle through
which iterative improvements in service provision can be
made [30]. The current 12 performance measures are
based on national clinical guidelines and key concepts
identified by previous research of the investigator group
and others. These performance measures, and their sub-
analyses, were further developed with the clinical hubs
using a co-design approach and feedback from partici-
pating ACCHS has been positive. The ATLAS network
also features a comprehensive, standardised and auto-
mated data collection and analysis infrastructure that
will facilitate expansion of the network. Moreover, the
use of GRHANITE and its hashed deidentifier, which
cannot be reverse-engineered but is the same for the
same individual in every setting, facilitates the synthesis
of ATLAS data with that of other surveillance systems
using GRHANITE, such as the Australian Collaboration
for Coordinated Enhanced Sentinel Surveillance
(ACCESS) [16] and Test Treat ANd GO2 [31] projects,
will give a more complete picture of service access and
health care delivery by individuals and/or by regions.
The establishment of the ATLAS surveillance network,
has enabled trust to be built between the researchers
and health services, and supported shared values of spirit
and integrity, reciprocity, respect, equity, cultural con-
tinuity, and responsibility in all of the network’s activ-
ities [32]. Because of the sensitive nature of the research
topic, trust and a highly ethical approach to data collec-
tion, management and reporting have been critical.
Recognition of the ACCHS’s continued ownership of the
contributed data has also been key, with an important
focus of the project being to facilitate the prompt return
of the data in a form readily accessible to health service
staff and strengthening capacity for health services to
control the analysis process.
Strengths
The ATLAS network has several key strengths: firstly,
the network of relationships built on trust and shared
core values between the research team and the ACCHS
sites. Without this, the surveillance system could not
operate. Secondly, the large number of ACCHS partici-
pating in the project contributes critical diversity and
representativeness to the surveillance system. Another
key strength is the inclusion of urban and inner-regional
ACCHS; the burden of STI and BBV in non-remote
Aboriginal populations is largely unknown and ATLAS
will be the first Aboriginal-specific surveillance network
to address this knowledge gap. Expansion of our activ-
ities to include data from complementary networks will
only strengthen this important component of our work.
Our development of GRHANITE and its ability to
interact with MMEx is novel and substantially contrib-
utes to secure access and inclusion of this popular EMR.
The parallel development of an externally-facing secure
online dashboard not only addresses issues of analytic
capacity in such a large and complex network but also
allows for improved access to current data and custom-
isable analyses for the ACCHS. Moreover, by automating
so much of the data collection, analysis and reporting
tasks, the sustainability of the ATLAS STI and BBV net-
work is increased and the infrastructure will be easy to
support beyond the life of its current funding.
Limitations
The ATLAS STI and BBV surveillance project cur-
rently has several limitations, most of which will be
overcome as the network matures. A major limitation
has been the impact of the time required to establish
approval for the implementation of our research. Des-
pite long-standing relationships between the research
team and the clinical hubs, significant time has had
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to be devoted to working with the clinical hubs to
determine an acceptable approach to data collection
and use and to engage ACCHS within the network.
Ultimately a strength of the ATLAS project, the im-
pact of this (ongoing) relationship-building process on
project timelines must be acknowledged. Similarly,
complex research governance and ethics approval pro-
cesses have had a greater impact on ATLAS than
would be the case for a non-Aboriginal surveillance
system. National mutual acceptance of ethical review
is largely inappropriate in the Aboriginal health sector, as
one community cannot know or speak on behalf of the
many independent and highly diverse Aboriginal commu-
nities across the country. Accordingly, in a national
research project, a large number of research governance
groups and ethics committees must be approached, which
leads to complex cycles of feedback and amendments and
substantially increases the time to establishment for net-
works like ATLAS.
More technical limitations have also been encountered,
such as the impact of staff turnover within the SAHMRI-
based team as well as some—but not all—of our partnering
and participating organisations. Other issues are associated
with the difficulties of designing and developing a robust
data infrastructure to collect and synthesise data sourced
from a large number of EMR systems, all of which seem to
be used by each ACCHS in a slightly different manner.
Again, the impact of these limitations will largely reduce as
the ATLAS system matures and, as in the case of issues
associated with the diversity of EMR in the network, will
ultimately prove to be a strength of the established surveil-
lance network.
Finally, as the ACCHS were not randomly selected, the
data is not representative of all ACCHS and will not
reflect testing, treatment and management data for all
Aboriginal communities in Australia. We do not currently
have reliable data to determine if there are significant
differences between the ACCHS that have been included
in this surveillance network and those that have not. How-
ever, participating ACCHS represent a wide geographical
spread of ACCHS, including metropolitan, regional,
remote and very remote communities. In addition, the
surveillance network has been developed in such a way
that it can be easily expanded in the future to include
more ACCHS and improve representation.
Conclusion
The ATLAS surveillance network is a unique data infra-
structure addressing an important knowledge gap in the
Aboriginal health sector. ATLAS will make an important
contribution to improved understanding of local, regional
and national patterns of STI and BBV to inform clinical
practice, policy, and program planning and implementation.
ATLAS is already strengthening relationships between
ACCHS and researchers; this strengthening is bound to
consolidate as the information exchange process matures.
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